The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years with the launch of novel topical drugs (e.g., Aerie Pharmaceuticals’ Rhopressa and Rocklatan, Bausch + Lomb’s Vyzulta). Although topical eye drops are the central pillar of OAG treatment, innovative approaches such as sustained-release formulations of some key OAG drugs (e.g., AbbVie’s Durysta) and developments in the field of devices for minimally invasive glaucoma surgery (MIGS) offer promising nontopical treatment options for ophthalmologists and glaucoma specialists treating OAG patients.
Geography: United States.
Primary Research: Survey of 102 U.S. ophthalmologists / glaucoma specialists.
Special Topics assesses key trends in dynamic disease areas. This report on glaucoma will help drug marketers and developers gain insight into the current and anticipated impact of newer-to-market and key emerging therapies and approaches on physician prescribing decisions for the treatment of glaucoma in the United States.